Enhanced diagnosis of multi-drug-resistant microbes using group association modeling and machine learning.

Journal: Nature communications
PMID:

Abstract

New solutions are needed to detect genotype-phenotype associations involved in microbial drug resistance. Herein, we describe a Group Association Model (GAM) that accurately identifies genetic variants linked to drug resistance and mitigates false-positive cross-resistance artifacts without prior knowledge. GAM analysis of 7,179 Mycobacterium tuberculosis (Mtb) isolates identifies gene targets for all analyzed drugs, revealing comparable performance but fewer cross-resistance artifacts than World Health Organization (WHO) mutation catalogue approach, which requires expert rules and precedents. GAM also reveals generalizability, demonstrating high predictive accuracy with 3,942 S. aureus isolates. GAM refinement by machine learning (ML) improves predictive accuracy with small or incomplete datasets. These findings were validated using 427 Mtb isolates from three sites, where GAM inputs are also found to be more suitable in ML prediction models than WHO inputs. GAM + ML could thus address the limitations of current drug resistance prediction methods to improve treatment decisions for drug-resistant microbial infections.

Authors

  • Julian G Saliba
    Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, New Orleans, LA, USA.
  • Wenshu Zheng
    Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, New Orleans, LA, USA. wzheng5@tulane.edu.
  • Qingbo Shu
    Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, New Orleans, LA, USA.
  • Liqiang Li
    Department of Clinical Laboratory, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
  • Chi Wu
    Department of Clinical Laboratory, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
  • Yi Xie
    Department of Plastic Surgery Peninsula Health Melbourne Victoria Australia.
  • Christopher J Lyon
    Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, New Orleans, LA, USA.
  • Jiuxin Qu
    Department of Clinical Laboratory, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
  • Hairong Huang
    National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing, China.
  • Binwu Ying
    Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610064, China. zhoujuan39@wchscu.cn.
  • Tony Ye Hu
    Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, New Orleans, LA, USA. tonyhu@tulane.edu.